CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Metagen Therapeutics›
News
Metagen Therapeutics logo

Metagen Therapeutics

Metagen Therapeutics develops gut microbiome treatments and medical services, including fecal microbiota transplantation.

Tsuruoka, Yamagata, JP🇯🇵
Founded
2020
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About Metagen Therapeutics

Development of Gut Microbiota Therapeutics, Metagen Therapeutics Raises ¥190 Million

BRIDGE

Development of Gut Microbiota Therapeutics, Metagen Therapeutics Raises ¥190 Million

Metagen Therapeutics, a company developing therapies and drugs utilizing gut microbiota, announced on the 4th that it has raised a total of...

Sep 7, 2026

Metagen Therapeutics Raises ¥3.52 Billion in Series B Funding for Fecal Microbiota Transplantation, Bringing Total to ¥5.46 Billion

BRIDGE

Metagen Therapeutics Raises ¥3.52 Billion in Series B Funding for Fecal Microbiota Transplantation, Bringing Total to ¥5.46 Billion

On the 26th, Metagen Therapeutics, which promotes medical and drug discovery based on gut microbiota research, announced the completion of...

Feb 27, 2026

Metagen Therapeutics, a Microbiome Drug Discovery Company, Raises Approximately ¥2.3 Billion in Series B

BRIDGE

Metagen Therapeutics, a Microbiome Drug Discovery Company, Raises Approximately ¥2.3 Billion in Series B

Metagen Therapeutics, a company engaged in microbiome drug discovery, announced on the 8th that it has raised a total of ¥2.32 billion in...

Sep 17, 2025

Metagen Therapeutics and FRONTEO Launch Joint Research on Globally Watched Microbiome Drug Discovery

FRONTEO USA

Metagen Therapeutics and FRONTEO Launch Joint Research on Globally Watched Microbiome Drug Discovery

Tokyo, Japan, 30 June, 2025 -Metagen Therapeutics, Inc. and FRONTEO, Inc. are pleased to announce the launch of a joint research...

Jun 29, 2025

Metagen Therapeutics and JSR, Alliance to Establish Microbiome Medicine Investigational Drug Manufacturing Facility

JSR Corporation

Metagen Therapeutics and JSR, Alliance to Establish Microbiome Medicine Investigational Drug Manufacturing Facility

Metagen Therapeutics, a microbiome drug discovery company, and JSR Corporation, a leading global materials innovation company, have signed...

Sep 12, 2024